Related Experiment Video
Updated: Sep 10, 2025

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
Published on: August 7, 2021
PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancers
Bang Li1, Jin-Qi Yu1, Zhenjiao Yang1
1Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Abstract:
PRMT5 is a promising target for cancer therapy. However, the first-generation PRMT5 inhibitors failed in the clinical trials due to the dose-limiting hematological toxicities, which could be attributed to the indiscriminate blockade of PRMT5 and the critical function of PRMT5 as an essential gene in regulating hematopoiesis. The second-generation MTA-cooperative PRMT5 synthetic lethal inhibitors could selectively inhibit PRMT5 activity in MTAP-del cancer cells while preserving its potency in MTAP-WT cells, presenting a promising precision oncology medicine. In this perspective, we analyzed the different binding modes between PRMT5·MTA and PRMT5·SAM complexes and highlighted the discovery of the second-generation MTA-cooperative PRMT5 inhibitors with the guidance of their cocrystal structures bound to the PRMT5·MTA complex. We also discussed the challenges and opportunities of these synthetic lethal inhibitors to shed light on future drug development.
Insights
Second-generation PRMT5 inhibitors offer a precision oncology approach by selectively targeting cancer cells with MTAP deletions. This strategy overcomes the hematological toxicities seen with earlier PRMT5 inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Protein arginine methyltransferase 5 (PRMT5) is a key target in cancer therapy.
- First-generation PRMT5 inhibitors caused dose-limiting hematological toxicities due to non-selective inhibition.
- PRMT5 is essential for normal hematopoiesis, complicating therapeutic strategies.
Purpose of the Study:
- To analyze binding modes of PRMT5 complexes.
- To highlight the development of second-generation MTA-cooperative PRMT5 inhibitors.
- To discuss challenges and opportunities for future PRMT5 inhibitor drug development.
Main Methods:
- Analysis of binding modes between PRMT5·MTA and PRMT5·SAM complexes.
- Utilizing cocrystal structures of PRMT5·MTA complexes.
- Review of synthetic lethal inhibitor strategies.
Main Results:
- Second-generation inhibitors selectively target PRMT5 in MTAP-deleted cancer cells.
- These inhibitors preserve PRMT5 function in MTAP-wildtype cells, reducing toxicity.
- Cocrystal structures guided the discovery of improved MTA-cooperative inhibitors.
Conclusions:
- MTA-cooperative PRMT5 inhibitors represent a promising precision oncology strategy.
- Selective inhibition overcomes toxicity issues of earlier PRMT5-targeted therapies.
- Further development holds potential for effective cancer treatment.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

